The AML samples with strong response to AC-4-130 and S63845 combination treatment comprised eight FLT3 mutated, five TET2 mutated AML, and one AML with IDH2 and DNMT3A mutations. This evidence concerns the gene DNMT3A and acute myeloid leukemia.